India, Aug. 18 -- Evogene Ltd. (EVGN) reported second-quarter and first-half 2026 financial results, highlighting continued progress in its transformation into a focused, AI-driven computational chemistry company serving the pharmaceutical and agricultural industries.
Over the past 18 months, Evogene has substantially streamlined its operations, cutting its workforce from 117 employees in December 2024 to 38 in August 2026, while reducing operating expenses and concentrating resources on opportunities with stronger commercial potential.
Evogene expects 2026 cash usage of approximately $8.5 million to $9.5 million, down from approximately $14.4 million in 2025 and $20.5 million in 2024. The company has also raised approximately $11.1 milli...